Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease

Jing Wang; Hiromi Iwasaki; Andrei Krivtsov; Phillip G. Febbo; Aaron R. Thorner; Patricia Ernst; Erna Anastasiadou; Jeffery L. Kutok; Scott C. Kogan; Sandra S. Zinkel; Jill K. Fisher; Jay L. Hess; Todd R. Golub; Scott A. Armstrong; Koichi Akashi; Stanley J. Korsmeyer

doi:10.1038/sj.emboj.7600521

Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease

Jing Wang, Hiromi Iwasaki, Andrei Krivtsov, Phillip G. Febbo, Aaron R. Thorner, Patricia Ernst, Erna Anastasiadou, Jeffery L. Kutok, Scott C. Kogan, Sandra S. Zinkel, Jill K. Fisher, Jay L. Hess, Todd R. Golub, Scott A. Armstrong, Koichi Akashi, Stanley J. Korsmeyer

Research output: Contribution to journal › Article › peer-review

90 Citations (Scopus)

Abstract

Chromosomal translocations that fuse the mixed lineage leukemia (MLL) gene with multiple partners typify acute leukemias of infancy as well as therapy-related leukemias. We utilized a conditional knockin strategy to bypass the embryonic lethality caused by MLL-CBP expression and to assess the immediate effects of induced MLL-CBP expression on hematopoiesis. Within days of activating MLL-CBP, the fusion protein selectively expanded granulocyte/ macrophage progenitors (GMP) and enhanced their self-renewal/proliferation. MLL-CBP altered the gene expression program of GMP, upregulating a subset of genes including Hox a9. Inhibition of Hox a9 expression by RNA interference demonstrated that MLL-CBP required Hox a9 for its enhanced cell expansion. Following exposure to sublethal γ-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myeloproliferative disorders. These represented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/ myeloproliferative disorder similar to that seen in humans possessing the t(11;16). This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations.

Original language	English
Pages (from-to)	368-381
Number of pages	14
Journal	EMBO Journal
Volume	24
Issue number	2
DOIs	https://doi.org/10.1038/sj.emboj.7600521
Publication status	Published - Jan 26 2005
Externally published	Yes

All Science Journal Classification (ASJC) codes

Neuroscience(all)
Molecular Biology
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)

Access to Document

10.1038/sj.emboj.7600521

Fingerprint Dive into the research topics of 'Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease'. Together they form a unique fingerprint.

Cite this

Wang, J., Iwasaki, H., Krivtsov, A., Febbo, P. G., Thorner, A. R., Ernst, P., Anastasiadou, E., Kutok, J. L., Kogan, S. C., Zinkel, S. S., Fisher, J. K., Hess, J. L., Golub, T. R., Armstrong, S. A., Akashi, K., & Korsmeyer, S. J. (2005). Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO Journal, 24(2), 368-381. https://doi.org/10.1038/sj.emboj.7600521

Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. / Wang, Jing; Iwasaki, Hiromi; Krivtsov, Andrei; Febbo, Phillip G.; Thorner, Aaron R.; Ernst, Patricia; Anastasiadou, Erna; Kutok, Jeffery L.; Kogan, Scott C.; Zinkel, Sandra S.; Fisher, Jill K.; Hess, Jay L.; Golub, Todd R.; Armstrong, Scott A.; Akashi, Koichi; Korsmeyer, Stanley J.

In: EMBO Journal, Vol. 24, No. 2, 26.01.2005, p. 368-381.

Research output: Contribution to journal › Article › peer-review

Wang, J, Iwasaki, H, Krivtsov, A, Febbo, PG, Thorner, AR, Ernst, P, Anastasiadou, E, Kutok, JL, Kogan, SC, Zinkel, SS, Fisher, JK, Hess, JL, Golub, TR, Armstrong, SA, Akashi, K & Korsmeyer, SJ 2005, 'Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease', EMBO Journal, vol. 24, no. 2, pp. 368-381. https://doi.org/10.1038/sj.emboj.7600521

Wang, Jing ; Iwasaki, Hiromi ; Krivtsov, Andrei ; Febbo, Phillip G. ; Thorner, Aaron R. ; Ernst, Patricia ; Anastasiadou, Erna ; Kutok, Jeffery L. ; Kogan, Scott C. ; Zinkel, Sandra S. ; Fisher, Jill K. ; Hess, Jay L. ; Golub, Todd R. ; Armstrong, Scott A. ; Akashi, Koichi ; Korsmeyer, Stanley J. / Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. In: EMBO Journal. 2005 ; Vol. 24, No. 2. pp. 368-381.

@article{23c48482220f4bb0b1d590eb1a0264b8,

title = "Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease",

abstract = "Chromosomal translocations that fuse the mixed lineage leukemia (MLL) gene with multiple partners typify acute leukemias of infancy as well as therapy-related leukemias. We utilized a conditional knockin strategy to bypass the embryonic lethality caused by MLL-CBP expression and to assess the immediate effects of induced MLL-CBP expression on hematopoiesis. Within days of activating MLL-CBP, the fusion protein selectively expanded granulocyte/ macrophage progenitors (GMP) and enhanced their self-renewal/proliferation. MLL-CBP altered the gene expression program of GMP, upregulating a subset of genes including Hox a9. Inhibition of Hox a9 expression by RNA interference demonstrated that MLL-CBP required Hox a9 for its enhanced cell expansion. Following exposure to sublethal γ-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myeloproliferative disorders. These represented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/ myeloproliferative disorder similar to that seen in humans possessing the t(11;16). This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations.",

author = "Jing Wang and Hiromi Iwasaki and Andrei Krivtsov and Febbo, {Phillip G.} and Thorner, {Aaron R.} and Patricia Ernst and Erna Anastasiadou and Kutok, {Jeffery L.} and Kogan, {Scott C.} and Zinkel, {Sandra S.} and Fisher, {Jill K.} and Hess, {Jay L.} and Golub, {Todd R.} and Armstrong, {Scott A.} and Koichi Akashi and Korsmeyer, {Stanley J.}",

year = "2005",

month = jan,

day = "26",

doi = "10.1038/sj.emboj.7600521",

language = "English",

volume = "24",

pages = "368--381",

journal = "EMBO Journal",

issn = "0261-4189",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease

AU - Wang, Jing

AU - Iwasaki, Hiromi

AU - Krivtsov, Andrei

AU - Febbo, Phillip G.

AU - Thorner, Aaron R.

AU - Ernst, Patricia

AU - Anastasiadou, Erna

AU - Kutok, Jeffery L.

AU - Kogan, Scott C.

AU - Zinkel, Sandra S.

AU - Fisher, Jill K.

AU - Hess, Jay L.

AU - Golub, Todd R.

AU - Armstrong, Scott A.

AU - Akashi, Koichi

AU - Korsmeyer, Stanley J.

PY - 2005/1/26

Y1 - 2005/1/26

N2 - Chromosomal translocations that fuse the mixed lineage leukemia (MLL) gene with multiple partners typify acute leukemias of infancy as well as therapy-related leukemias. We utilized a conditional knockin strategy to bypass the embryonic lethality caused by MLL-CBP expression and to assess the immediate effects of induced MLL-CBP expression on hematopoiesis. Within days of activating MLL-CBP, the fusion protein selectively expanded granulocyte/ macrophage progenitors (GMP) and enhanced their self-renewal/proliferation. MLL-CBP altered the gene expression program of GMP, upregulating a subset of genes including Hox a9. Inhibition of Hox a9 expression by RNA interference demonstrated that MLL-CBP required Hox a9 for its enhanced cell expansion. Following exposure to sublethal γ-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myeloproliferative disorders. These represented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/ myeloproliferative disorder similar to that seen in humans possessing the t(11;16). This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations.

AB - Chromosomal translocations that fuse the mixed lineage leukemia (MLL) gene with multiple partners typify acute leukemias of infancy as well as therapy-related leukemias. We utilized a conditional knockin strategy to bypass the embryonic lethality caused by MLL-CBP expression and to assess the immediate effects of induced MLL-CBP expression on hematopoiesis. Within days of activating MLL-CBP, the fusion protein selectively expanded granulocyte/ macrophage progenitors (GMP) and enhanced their self-renewal/proliferation. MLL-CBP altered the gene expression program of GMP, upregulating a subset of genes including Hox a9. Inhibition of Hox a9 expression by RNA interference demonstrated that MLL-CBP required Hox a9 for its enhanced cell expansion. Following exposure to sublethal γ-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myeloproliferative disorders. These represented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/ myeloproliferative disorder similar to that seen in humans possessing the t(11;16). This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations.

UR - http://www.scopus.com/inward/record.url?scp=13444311619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444311619&partnerID=8YFLogxK

U2 - 10.1038/sj.emboj.7600521

DO - 10.1038/sj.emboj.7600521

M3 - Article

C2 - 15635450

AN - SCOPUS:13444311619

VL - 24

SP - 368

EP - 381

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 2

ER -